CD147 and PCSK9 as Predictors of Cancer in Patients with Type 2 Diabetes: A Comparative Study with Healthy Individuals

Diabetes has a higher cancer prevalence and a poorer prognosis than nondiabetes. Traditional parameters of blood pressure, sugar, and lipids unmet cancer prognosis. Novel biomarkers that predict the possibility of cancer development and mortality are still desirable in the clinic. 141 patients with type 2 diabetes and 172 healthy individuals with observation are enrolled. The differentiation cluster 147 (CD147), oxidized low-density lipoprotein (oxLDL), antibody (oxLDL-Ab), proprotein convertase subtilisin/kexin type 9 (PCSK9), and cyclophilin A (CyP A) were examined. Cancer morbidity and all-cause mortality were compared between the diabetic and control group. Body mass index (BMI) ≥ 27 kg/m2 (37.6% vs. 10.6%, p < 0.001), 10-year mortality rate (35% vs. 2.3%, p < 0.001), and cancer morbidity (16% vs. 5.23%, p < 0.001) were higher in the diabetic group. Obese diabetes had high oxLDL, soluble intercellular adhesion molecule-1-1 (sICAM-1), PCSK9, CyP A, and CD147. Deceased diabetes had a higher cancer rate and a low CD147 level. CD147 and PCSK9 levels show predictive efficacy in cancer and diabetes without obesity (area under the curve [AUC], 0.665) and diabetes and obesity (AUC, 0.726), respectively. CD147 and PCSK9 levels were better predictors of cancer in diabetes, regardless of whether they were obese or not.